A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD

Trial Profile

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms HONOR
  • Sponsors Tonix Pharmaceuticals Holding Corp
  • Most Recent Events

    • 29 Aug 2017 According to a Tonix Pharmaceuticals Holding Corp media release, design of this study were presented at the 2017 Military Health System Research Symposium.
    • 21 Aug 2017 According to a Tonix Pharmaceuticals Holding Corp media release, design of this study will be will presented at the 2017 Military Health System Research Symposium, August 2017.
    • 12 Jun 2017 According to a Tonix Pharmaceuticals Holding Corp media release, this study will be presented at the 2017 Marcum MicroCap Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top